Daratumumab for Patients With Light Chain Amyloidosis — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Daratumumab for Patients With Light Chain Amyloidosis — Stella

Recruiting

Back to Light Chain (AL) Amyloidosis trials

Not a traditional drug trial — this study doesn't follow the standard phase structure.

Trial locations(1 site)

China

National Clinical Research Center for Kidney Diseases, Jinling Hospital, Nanjing, Jiangsu

Key details

Sponsor

Nanjing University School of Medicine

Enrollment target

~100 participants

Started

January 2023

Primary completion

December 2025

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

18 Years – 75 Years

Last updated April 2024

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov